Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–9.

Article  PubMed  PubMed Central  Google Scholar 

Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol. 2001;52(1):77–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Insani WN, Whittlesea C, Alwafi H, Man KKC, Chapman S, Wei L. Prevalence of adverse drug reactions in the primary care setting: a systematic review and meta-analysis. PLoS ONE. 2021;16(5):e0252161.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lauschke VM, Ingelman-Sundberg M. Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing. Eur J Pharm Sci. 2019;130:65–77.

Article  CAS  PubMed  Google Scholar 

Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103–41.

Article  CAS  PubMed  Google Scholar 

Zhang HF, Wang HH, Gao N, Wei JY, Tian X, Zhao Y, et al. Physiological content and intrinsic activities of 10 cytochrome P450 isoforms in human normal liver microsomes. J Pharmacol Exp Ther. 2016;358(1):83–93.

Article  PubMed  Google Scholar 

Daly AK, Rettie AE, Fowler DM, Miners JO. Pharmacogenomics of CYP2C9: functional and clinical considerations. J Pers Med. 2017;8(1):1.

Article  PubMed  PubMed Central  Google Scholar 

Yasar U, Bennet AM, Eliasson E, Lundgren S, Wiman B, De Faire U, et al. Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics. 2003;13(12):715–20.

Article  CAS  PubMed  Google Scholar 

Rettie AE, Haining RL, Bajpai M, Levy RH. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res. 1999;35(3):253–5.

Article  CAS  PubMed  Google Scholar 

Niinuma Y, Saito T, Takahashi M, Tsukada C, Ito M, Hirasawa N, et al. Functional characterization of 32 CYP2C9 allelic variants. Pharmacogenomics J. 2014;14(2):107–14.

Article  CAS  PubMed  Google Scholar 

Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005;77(1):1–16.

Article  CAS  PubMed  Google Scholar 

Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014;96(5):542–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Van Booven D, Marsh S, McLeod H, Carrillo MW, Sangkuhl K, Klein TE, et al. Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics. 2010;20(4):277–81.

Article  PubMed  PubMed Central  Google Scholar 

Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics. 2009;19(2):170–9.

Article  CAS  PubMed  Google Scholar 

Céspedes-Garro C, Fricke-Galindo I, Naranjo ME, Rodrigues-Soares F, Fariñas H, de Andrés F, et al. Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes. Expert Opin Drug Metab Toxicol. 2015;11(12):1893–905.

Article  PubMed  Google Scholar 

Sangkuhl K, Claudio-Campos K, Cavallari LH, Agundez JAG, Whirl-Carrillo M, Duconge J, et al. PharmVar GeneFocus: CYP2C9. Clin Pharmacol Ther. 2021;110(3):662–76.

Article  CAS  PubMed  Google Scholar 

Nizamuddin S, Dubey S, Singh S, Sharma S, Machha P, Thangaraj K. CYP2C9 variations and their pharmacogenetic implications among diverse South Asian populations. Pharmgenomics Pers Med. 2021;14:135–47.

PubMed  PubMed Central  Google Scholar 

Zhou Y, Lauschke VM. The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data. Pharmacogenomics J. 2022.

Costa MD, Pereira JB, Pala M, Fernandes V, Olivieri A, Achilli A, et al. A substantial prehistoric European ancestry amongst Ashkenazi maternal lineages. Nat Commun. 2013;4:2543.

Article  PubMed  Google Scholar 

Hill C, Soares P, Mormina M, Macaulay V, Meehan W, Blackburn J, et al. Phylogeography and ethnogenesis of aboriginal Southeast Asians. Mol Biol Evol. 2006;23(12):2480–91.

Article  CAS  PubMed  Google Scholar 

Xu S, Jin L. A genome-wide analysis of admixture in Uyghurs and a high-density admixture map for disease-gene discovery. Am J Hum Genet. 2008;83(3):322–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Silva-Zolezzi I, Hidalgo-Miranda A, Estrada-Gil J, Fernandez-Lopez JC, Uribe-Figueroa L, Contreras A, et al. Analysis of genomic diversity in Mexican Mestizo populations to develop genomic medicine in Mexico. Proc Natl Acad Sci USA. 2009;106(21):8611–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saldaña-Cruz AM, León-Moreno LC, Sánchez-Corona J, Santiago DA, Mendoza-Carrera F, Castro-Martínez XH, et al. CYP2C9 and CYP2C19 Allele and haplotype distributions in four mestizo populations from Western Mexico: An interethnic comparative study. Genet Test Mol Biomarkers. 2016;20(11):702–9.

Article  PubMed  Google Scholar 

Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak N, et al. A European spectrum of pharmacogenomic biomarkers: implications for clinical pharmacogenomics. PLoS ONE. 2016;11(9):e0162866.

Article  PubMed  PubMed Central  Google Scholar 

Nordestgaard BG, Kontula K, Benn M, Dahlöf B, de Faire U, Edelman JM, et al. Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study. Pharmacogenet Genomics. 2010;20(2):77–85.

Article  CAS  PubMed  Google Scholar 

Jaya Shankar A, Jadhao S, Hoy W, Foote SJ, Patel HR, Scaria V, et al. Pharmacogenomic analysis of a genetically distinct Indigenous population. Pharmacogenomics J. 2022;22(2):100–8.

Article  CAS  PubMed  Google Scholar 

Suarez-Kurtz G, Parra EJ. Population diversity in pharmacogenetics: a latin American perspective. Adv Pharmacol. 2018;83:133–54.

Article  CAS  PubMed  Google Scholar 

Suarez-Kurtz G. Pharmacogenetics in the Brazilian population. Front Pharmacol. 2010;1:118.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fekete F, Mangó K, Déri M, Incze E, Minus A, Monostory K. Impact of genetic and non-genetic factors on hepatic CYP2C9 expression and activity in Hungarian subjects. Sci Rep. 2021;11(1):17081.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Varshney E, Saha N, Tandon M, Shrivastava V, Ali S. Genotype-phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region. Eur J Drug Metab Pharmacokinet. 2013;38(4):275–82.

Article  CAS  PubMed  Google Scholar 

Ciccacci C, Falconi M, Paolillo N, Oteri F, Forte V, Novelli G, et al. Characterization of a novel CYP2C9 gene mutation and structural bioinformatic protein analysis in a warfarin hypersensitive patient. Pharmacogenet Genomics. 2011;21(6):344–6.

Article  CAS  PubMed  Google Scholar 

Borgiani P, Ciccacci C, Forte V, Romano S, Federici G, Novelli G. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics. 2007;8(11):1545–50.

Article  CAS  PubMed  Google Scholar 

Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353(9154):717–9.

Article  CAS  PubMed  Google Scholar 

Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369(24):2294–303.

Article  CAS  PubMed  Google Scholar 

Mega JL, Walker JR, Ruff CT, Vandell AG, Nordio F, Deenadayalu N, et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385(9984):2280–7.

Article  CAS  PubMed  Google Scholar 

Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, et al. Clinical pharmacogenetics implementation consortium (CPIC) Guideline for pharmacogenetics-Guided Warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017;102(3):397–404.

Article  CAS